Lupin’s Global Rise & FarMart’s Profitability

The Genesis and Global Reach of Pharma Giant Lupin

The remarkable story of Lupin, a pharmaceutical powerhouse, is deeply intertwined with the vision of its founder, Desh Bandhu Gupta. Gupta, who rose from humble beginnings in a home lacking basic amenities like electricity and water, established a company that now stands as a testament to Indian entrepreneurial spirit. Lupin’s global footprint is substantial, notably supplying an estimated 20 billion pills annually to the United States market, underscoring its critical role in international healthcare supply chains.

Manish Sabharwal, Gupta’s son-in-law and a noted figure in the business world, has chronicled this inspiring journey in his book, ‘Made in India,’ co-authored with Sundeep Khanna. Sabharwal highlights the paradoxical success of the Indian pharmaceutical sector, with India ranking 128th in per capita GDP yet producing a significant portion of the world’s medicines. Lupin’s trajectory, from its inception to its current global stature, is a key narrative within this broader industry success story.

Navigating Challenges and Strategic Pivots

The path to success for Lupin was not without its significant challenges, often stemming from the founder’s own strategic decisions. Sabharwal recounts a particularly difficult period when Gupta made substantial gambles in the real estate and stock markets, leading to a severe downturn. The company’s market value plummeted dramatically, from approximately Rs 1,000 crore to Rs 286 crore, a stark reminder of the inherent risks in business ventures. These experiences shaped the company’s resilience and strategic approach in subsequent years.

DBG’s early years in business were also characterized by the necessity of navigating complex relationships with the state before engaging with the market. This environment, prevalent in India’s developing economy, required a unique set of skills and adaptability. The company’s ability to overcome these internal and external hurdles speaks volumes about its foundational strength and leadership.

FarMart Achieves EBITDA Profitability, Signals Growth

In the burgeoning agri-food technology sector, FarMart has emerged as a significant player, announcing a major milestone: achieving EBITDA profitability in the fourth quarter of the fiscal year 2026. This achievement marks a crucial turning point for the Gurugram-based platform, demonstrating its robust operational efficiency and sustainable business model. The company concluded the fiscal year with an impressive annualized revenue run rate of $400 million, equivalent to approximately Rs 3,600 crore.

This substantial run rate is based on the performance observed in Q4 FY26, indicating a strong upward trajectory. FarMart’s gross order value (GOV) for the entire fiscal year exceeded Rs 2,800 crore, representing a significant 50% year-on-year increase from Rs 1,961 crore recorded in FY25. This growth underscores the increasing demand for its services and its expanding market share within the agricultural supply chain.

FarMart’s Financial Strategy and Investor Confidence

FarMart’s financial strategy has been instrumental in its growth and recent profitability. The company has successfully raised over $50 million in funding across various investment rounds from prominent investors such as Stride Ventures, Trifecta Capital, General Catalyst, and Omidyar Network. This investor confidence reflects the market’s belief in FarMart’s business model and its potential for continued expansion.

Beyond traditional equity funding, FarMart has strategically leveraged institutional capital through innovative financing mechanisms. The company has utilized structured financing, including receivables securitisation, to enhance its working capital availability. This approach not only improves operational flexibility but also reduces its reliance on conventional lending channels, positioning it for more agile and efficient growth in the competitive agritech landscape.